imiquimod has been researched along with mannitol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedke, J; Dietz, K; Feyerabend, S; Gouttefangeas, C; Hennenlotter, J; Kuczyk, M; Pascolo, S; Rammensee, HG; Stenzl, A; Stevanovic, S; Wernet, D | 1 |
| Battaglia, F; Boccardo, F; Carmignani, G; Cittadini, G; Criscuolo, D; Fenoglio, D; Ferrera, F; Filaci, G; Indiveri, F; Kalli, F; Murdaca, G; Negrini, S; Parodi, A; Puppo, F; Sciallero, S; Setti, M; Sobrero, A; Tomasello, L; Traverso, P | 1 |
1 trial(s) available for imiquimod and mannitol
| Article | Year |
|---|---|
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
Topics: Aged; Aminoquinolines; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A2 Antigen; Hormones; Humans; Hyperthermia, Induced; Imiquimod; Magnetic Resonance Imaging; Male; Mannitol; Middle Aged; Mucin-1; Oleic Acids; Peptide Fragments; Prostate-Specific Antigen; Prostatic Neoplasms; Protamines; RNA, Messenger; Secondary Prevention; Tomography, X-Ray Computed | 2009 |
1 other study(ies) available for imiquimod and mannitol
| Article | Year |
|---|---|
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aminoquinolines; Antigens, Neoplasm; Cancer Vaccines; Cell Proliferation; Combined Modality Therapy; Cytotoxicity, Immunologic; Humans; Imiquimod; Interferon-gamma; Kidney Neoplasms; Male; Mannitol; Middle Aged; Neoplasm Staging; Oleic Acids; Peptides; Phenotype; Prostatic Neoplasms; Telomerase; Treatment Outcome | 2013 |